New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
07:24 EDTECYTEndocyte shares can advance even if NSLC treatment fails, says RBC Capital
RBC Capital is upbeat on Endocyte's pipeline and believes that the company's long-term fundamentals have improved. The firm thinks the stock's risk/reward ratio is positive at current levels and keeps an Outperform rating on the shares.
News For ECYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ECYT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use